NCT00875160View on ClinicalTrials.gov

A Study in Type 1 Gaucher Patients to Evaluate the Pharmacokinetics, Safety and Pharmacodynamics of AT2101

PHASE1TerminatedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

April 30, 2009

Primary Completion Date

July 31, 2009

Study Completion Date

July 31, 2009

Conditions
Type 1 Gaucher Disease
Interventions
DRUG

AT2101

225mg (nine 25mg capsules total dose) to be taken by mouth every day for 9 days (Study Days 1, 3-10)

Trial Locations (2)

33025

Comprehensive Phase One, Miramar

SE1 1YR

Guy's Drug Research Unit, London

Sponsors
All Listed Sponsors
lead

Amicus Therapeutics

INDUSTRY